You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Johnson and Johnson
Mallinckrodt
Harvard Business School
Medtronic

Last Updated: February 23, 2024

CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Desvenlafaxine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00256685 ↗ Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2004-09-01 The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
NCT00277823 ↗ Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-02-01 The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
NCT00283842 ↗ Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-03-01 The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NCT00300378 ↗ Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-03-01 The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.
NCT00329147 ↗ Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-05-01 The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
NCT00329186 ↗ Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-05-01 The purpose of this study is to determine if the relative difference in PK between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
NCT00369343 ↗ Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-09-01 Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Desvenlafaxine

Condition Name

Condition Name for Desvenlafaxine
Intervention Trials
Major Depressive Disorder 27
Depressive Disorder, Major 9
Depression 8
Vasomotor Symptoms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Desvenlafaxine
Intervention Trials
Depression 46
Depressive Disorder 45
Depressive Disorder, Major 42
Disease 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Desvenlafaxine

Trials by Country

Trials by Country for Desvenlafaxine
Location Trials
United States 499
Canada 31
Japan 21
Mexico 9
South Africa 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Desvenlafaxine
Location Trials
Florida 26
Ohio 23
California 22
Texas 20
Georgia 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Desvenlafaxine

Clinical Trial Phase

Clinical Trial Phase for Desvenlafaxine
Clinical Trial Phase Trials
Phase 4 17
Phase 3 30
Phase 2/Phase 3 3
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Desvenlafaxine
Clinical Trial Phase Trials
Completed 55
Unknown status 6
Terminated 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Desvenlafaxine

Sponsor Name

Sponsor Name for Desvenlafaxine
Sponsor Trials
Pfizer 27
Wyeth is now a wholly owned subsidiary of Pfizer 25
Luye Pharma Group Ltd. 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Desvenlafaxine
Sponsor Trials
Industry 61
Other 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Johnson and Johnson
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.